Section of Nephrology, Baylor College of Medicine, Houston, Texas; Baker Institute for Public Policy, Rice University, Houston Texas; Center for Innovations in Quality, Effectiveness and Safety, Baylor College of Medicine, Houston, Texas.
Center for Innovations in Quality, Effectiveness and Safety, Baylor College of Medicine, Houston, Texas; Michael E. DeBakey VA Medical Center, Houston, Texas; Section of Health Services Research, Department of Medicine, Baylor College of Medicine, Houston Texas.
Clin Ther. 2023 Mar;45(3):272-276. doi: 10.1016/j.clinthera.2023.01.015. Epub 2023 Feb 25.
Dialysis care in the United States is expensive and is mostly paid for by Medicare. To reduce the cost of providing dialysis services, the federal government has relied on a law that designates Medicare as a secondary payer in the first 30 months of dialysis. During this period, private health insurers are the primary payer and pay for the majority of dialysis-related costs. Private health insurers often pay substantially higher prices for dialysis care than does Medicare, possibly due to highly concentrated dialysis-provider markets. A perspective by Boumil and Curfmin in this journal discusses how a recent ruling by the US Supreme Court may limit Medicare's role as a secondary payer, potentially altering the economic relationship between dialysis providers and private insurers. Boumil and Curfmin discuss how these changes may ultimately promote competition in dialysis-provider markets and lower dialysis-related costs paid by private health insurers. We compare this viewpoint to responses and concerns voiced by other stakeholders in the kidney-care community and outline additional ways in which the Supreme Court's ruling may affect competition in dialysis markets and prices paid for dialysis by private insurers.
美国的透析护理费用昂贵,主要由医疗保险(Medicare)支付。为了降低提供透析服务的成本,联邦政府依赖一项法律,规定在透析的头 30 个月内,医疗保险作为第二付款人。在此期间,私人健康保险公司是主要付款人,并支付大多数与透析相关的费用。私人健康保险公司为透析护理支付的价格往往远高于医疗保险,这可能是由于透析服务提供商市场高度集中所致。本期杂志中的一篇观点文章讨论了美国最高法院最近的一项裁决可能如何限制医疗保险作为第二付款人的作用,从而改变透析服务提供商和私人保险公司之间的经济关系。Boumil 和 Curfmin 讨论了这些变化最终如何促进透析服务提供商市场的竞争,并降低私人健康保险公司支付的透析相关费用。我们将这一观点与肾脏护理界其他利益相关者表达的回应和关切进行了比较,并概述了最高法院的裁决可能以其他方式影响透析市场的竞争和私人保险公司为透析支付的价格。